ALT Pemvidutide Cuts AUD Heavy Drinking in Phase 2

Altimmune (NASDAQ: ALT) reported positive topline results from the RECLAIM Phase 2 trial on July 28, showing its dual GLP-1/glucagon agonist pemvidutide significantly reduced heavy drinking in patients with alcohol use disorder (AUD). It is the first Phase 2 evidence that a GLP-1-class drug can treat addiction, extending the weight-loss drug class into a new therapeutic area.

Pemvidutide (2.4 mg weekly) cut heavy drinking days by 4.20 per week versus 2.75 for placebo (LS mean difference -1.45, p=0.0014), meeting the primary endpoint. Every secondary endpoint was positive: 64.4% of treated patients achieved a two-level reduction in WHO Risk Drinking Levels versus 34.8% on placebo (OR 3.31, p=0.0049), and 42.2% reported zero heavy drinking days in the final four weeks versus 17.4% for placebo.

The blood biomarker data is the hard evidence. PEth, a direct measure of alcohol consumption in red blood cells, dropped 153.4 points in the pemvidutide arm versus a 22-point increase in placebo (p<0.0001). That is a 38% reduction in measured alcohol intake for treated patients against a 5.9% rise for placebo. Blood biomarkers matter because self-reported drinking data is notoriously unreliable; PEth confirms patients actually drank less, not just said they did.

RECLAIM enrolled approximately 100 patients with AUD and BMI above 25, randomized 1:1 to pemvidutide or placebo over 24 weeks (NCT06987513). Safety was consistent with the GLP-1 class profile: nausea (44% vs 24% placebo), vomiting (18% vs 6%), and constipation (26% vs 6%), mostly mild to moderate. Treatment discontinuations were 20% for pemvidutide versus 22% for placebo.

Altimmune closed at $2.99 on July 28, down $0.17 from the prior session, with a market cap of approximately $576 million. The stock barely moved on the news, reflecting investor focus on pemvidutide’s Phase 3 MASH program (PERFORMA, initiating H2 2026) rather than the AUD indication, which is years from an NDA filing. An End-of-Phase 2 meeting with the FDA is planned for AUD.

Pemvidutide is a balanced 1:1 glucagon/GLP-1 dual receptor agonist. The glucagon receptor component targets liver fat, inflammation, and fibrosis directly, while the GLP-1 component mediates appetite suppression and weight loss and may modulate reward pathways tied to craving. That dual mechanism is why the same drug is in Phase 3 for MASH and now shows efficacy in AUD, two conditions linked by liver pathology.

The competitive context for AUD is thin. Only three FDA-approved drugs exist: naltrexone (1994), acamprosate (2004), and disulfiram, all decades old with modest efficacy. Fewer than 2% of the estimated 28 million US adults with AUD use any of them. A GLP-1-class drug with objective biomarker validation would be a new option in a field that has not seen innovation in over 20 years. The same liver pathology connects AUD to MASH, where Madrigal’s Rezdiffra became the first approved drug and where pemvidutide is heading to Phase 3.

The risk is execution capacity. Altimmune is a microcap preparing a Phase 3 MASH trial while running the RESTORE Phase 2 in alcohol-associated liver disease and now pursuing AUD on top. Running two registrational-track programs simultaneously on a $576 million market cap is capital-intensive. The company reported $535 million in cash at the end of Q1 2026, enough to start PERFORMA but not enough to fund three programs to completion without a partner or dilution.

What to watch next: the End-of-Phase 2 meeting with the FDA for AUD, where the registrational path will be defined. The RECLAIM data is strong enough to support a Phase 3 program, but Altimmune must decide whether AUD is a priority or a strategic option that waits behind MASH.